BostonGene Earns Recognition From Cancer Cell for Its State-of-the-Art Technology in Cancer Research and Oncology

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene today announced its publication, “Conserved pan-cancer microenvironment subtypes predict response to immunotherapy,” has been selected by Cancer Cell as one of ten research articles that represent cutting-edge areas of cancer research and oncology in 2021.

The manuscript describes a transcriptomic-based tumor classification platform that identified four unique tumor microenvironment subtypes across 20 different cancers, predicting prognosis and response to immune checkpoint blockade. BostonGene also created a personalized tumor map to visually depict the key molecular and immune characteristics of each tumor. The microenvironment classification platform and tumor map provide a clinically useful and robust methodology for response prediction and incorporate precision medicine strategies across varied cancer types.

“We are thrilled to be recognized by Cancer Cell for our innovative multi-platform analytics combined with cutting-edge software to improve patient outcomes,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our findings underscore the power of integrated analysis to uncover unique and clinically applicable characteristics of the tumor microenvironment, and we are committed to enabling doctors to personalize therapy for cancer patients.”

The research results provided the foundation to launch BostonGene Tumor Portrait^TM Tests, which are designed to reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.

About BostonGene Corporation
BostonGene’s mission is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait^TM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait^TM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.